Correlation Engine 2.0
Clear Search sequence regions

Sizes of these terms reflect their relevance to your search.

This review discusses the rational for further studies of COX-2 inhibitors-NO releaser hybrids (NO-Coxibs) in the pharmacological treatment of the airway inflammation in Cystic Fibrosis (CF). Our research group developed several classes of NO-Coxibs for the pharmacological treatment of arthritis, and among them several compounds showed an outstanding in vivo efficacy and good pharmacokinetic properties. The good antiinflammatory properties displayed by these compounds during the previous screening could, by itself, suggest appropriate candidates for further testing in CF. Copyright © 2020 Elsevier Masson SAS. All rights reserved.


Sara Consalvi, Giovanna Poce, Carla Ghelardini, Lorenzo Di Cesare Mannelli, Paola Patrignani, Annalisa Bruno, Maurizio Anzini, Vincenzo Calderone, Alma Martelli, Lara Testai, Antonio Giordani, Mariangela Biava. Therapeutic potential for coxibs-nitric oxide releasing hybrids in cystic fibrosis. European journal of medicinal chemistry. 2021 Jan 15;210:112983

Expand section icon Mesh Tags

Expand section icon Substances

PMID: 33168231

View Full Text